Clinical response to interferon-β-1a may be linked to low baseline circulating BDCA1 myeloid dendritic cells. Differential role of circulating dendritic cells and CD4+ regulatory T-cells in relapsing-remitting multiple sclerosis: A 1-year longitudinal study

Journal of Neuroimmunology

Volumn 212, Issue 1-2, 2009, Pages 112-120

  de Andrés, Clara ^a   Aristimuño, Carol ^a   Bartolomé, Manuel ^b   de las Heras, Virginia ^b   Martínez Ginés, Ma Luisa ^a   Arroyo, Rafael ^b   Fernández Cruz, Eduardo ^a   Sánchez Ramón, Silvia ^a  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^b HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

Dendritic cells; Interferon beta 1a; Multiple sclerosis; Regulatory T cells; Responders

Indexed keywords

BETA1A INTERFERON; CD123 ANTIGEN; CD4 ANTIGEN; METHYLPREDNISOLONE;

ADULT; AGE DISTRIBUTION; ANTIGEN EXPRESSION; ANTIGEN FUNCTION; ARTICLE; BONE MARROW CELL; CD4+ T LYMPHOCYTE; CELL DIFFERENTIATION; CLINICAL ARTICLE; CONTROLLED STUDY; DENDRITIC CELL; EXPANDED DISABILITY STATUS SCALE; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; LONGITUDINAL STUDY; MALE; MULTIPLE SCLEROSIS; OBSERVATIONAL STUDY; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SEX DIFFERENCE; T LYMPHOCYTE ACTIVATION; TREATMENT OUTCOME;

ADULT; ANTIGENS, SURFACE; DENDRITIC CELLS; FEMALE; HUMANS; INTERFERON-BETA; LONGITUDINAL STUDIES; MALE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PROSPECTIVE STUDIES; RECURRENCE; T-LYMPHOCYTES, REGULATORY;

EID: 67649873307     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2009.04.009     Document Type: Article

References (48)

1. Banchereau J., and Steinman R.M. Dendritic cells and the control of immunity. Nature 392 (1998) 245-252
2. Beck J.R., and Shultz E.K. The use of relative operating characteristic (ROC) curves in test performance evaluation. Arch. Pathol. Lab. Med. 110 (1986) 13-20
3. Bielekova B., and Martin R. Development of biomarkers in multiple sclerosis. Brain 127 (2004) 1463-1478
4. Cederblad B., Blomberg S., Vallin H., Perers A., Alm G.V., and Ronnblom L. Patients with systemic lupus erythematosus have reduced numbers of circulating natural interferon-alpha-producing cells. J. Autoimmun. 11 (1998) 465-470
5. Compstom A., and Coles A. Multiple sclerosis. Lancet 359 (2002) 1221-1231
6. De Andrés, C., Vicente, A., Sánchez-Ramón, S., Sacedón, R., Gutierrez, C., Zapata, A., 2000. High numbers of activated dendritic cells in blood and cerebrospinal fluid of multiple sclerosis patients. Rev. Neurol. (Paris) 156, p. S154.
7. De Andrés, C., Aristimuño, C., Martínez-Ginés, M.L., De las Heras, V., Giménez-Roldán, S., Fernández-Cruz, E., et al., 2004a. Longitudinal Study of the In Vivo Effects of Beta-Interferon-1a on Dendritic Cells' Subsets and Regulatory T-cells in Relapsing-Remitting Multiple Sclerosis Patients. Mult. Scler. Vol. 10, (Suppl 2), S250.
8. de Andres C., Rodriguez-Sainz M.C., Munoz-Fernandez M.A., Lopez-Lazareno N., Rodriguez-Mahou M., Vicente A., et al. Short-term sequential analysis of sex hormones and helper T cells type 1 (Th1) and helper T cells type 2 (Th2) cytokines during and after multiple sclerosis relapse. Eur. Cytokine Netw. 15 (2004) 197-202
9. de Andres C., Aristimuno C., de Las Heras V., Martinez-Gines M.L., Bartolome M., Arroyo R., et al. Interferon beta-1a therapy enhances CD4+ regulatory T-cell function: an ex vivo and in vitro longitudinal study in relapsing-remitting multiple sclerosis. J. Neuroimmunol. 182 (2007) 204-211
10. Dhib-Jalbut S. Mechanisms of action of interferons and glatiramer acetate in multiple sclerosis. Neurology 58 (2002) S3-S9
11. Donaghy H., Pozniak A., Gazzard B., Qazi N., Gilmour J., Gotch F., et al. Loss of blood CD11c(+) myeloid and CD11c(-) plasmacytoid dendritic cells in patients with HIV-1 infection correlates with HIV-1 RNA virus load. Blood 98 (2001) 2574-2576
12. Donaghy H., Stebbing J., and Patterson S. Antigen presentation and the role of dendritic cells in HIV. Curr. Opin. Infect. Dis. 17 (2004) 1-6
13. Francis G.S., Rice G.P., and Alsop J.C. Interferon beta-1a in MS: results following development of neutralizing antibodies in PRISMS. Neurology 65 (2005) 48-55
14. Fukazawa T., Kikuchi S., Niino M., Yabe I., Miyagishi R., Fukaura H., et al. Attack-related severity: a key factor in understanding the spectrum of idiopathic inflammatory demyelinating disorders. J. Neurol. Sci. 225 (2004) 71-78
15. Gill M.A., Blanco P., Arce E., Pascual V., Banchereau J., and Palucka A.K. Blood dendritic cells and DC-poietins in systemic lupus erythematosus. Hum. Immunol. 63 (2002) 1172-1180
16. Hafler D.A. Multiple sclerosis. J. Clin. Invest. 113 (2004) 788-794
17. Hafler D.A., Slavik J.M., Anderson D.E., O'Connor K.C., De Jager P., and Baecher-Allan C. Multiple sclerosis. Immunol. Rev. 204 (2005) 208-231
18. Huang Y.M., Kouwenhoven M., Jin Y.P., Press R., Huang W.X., and Link H. Dendritic cells derived from patients with multiple sclerosis show high CD1a and low CD86 expression. Mult. Scler. 7 (2001) 95-99
19. Javed A., and Reder A.T. Therapeutic role of beta-interferons in multiple sclerosis. Pharmacol. Ther. 110 (2006) 35-56
20. Khoury S.J., Guttmann C.R., Orav E.J., Kikinis R., Jolesz F.A., and Weiner H.L. Changes in activated T cells in the blood correlate with disease activity in multiple sclerosis. Arch. Neurol. 57 (2000) 1183-1189
21. Kohrgruber N., Halanek N., Groger M., Winter D., Rappersberger K., Schmitt-Egenolf M., et al. Survival, maturation, and function of CD11c- and CD11c+ peripheral blood dendritic cells are differentially regulated by cytokines. J. Immunol. 163 (1999) 3250-3259
22. Kunitani H., Shimizu Y., Murata H., Higuchi K., and Watanabe A. Phenotypic analysis of circulating and intrahepatic dendritic cell subsets in patients with chronic liver diseases. J. Hepatol. 36 (2002) 734-741
23. Kurtzke J. Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology 33 (1983) 1444-1452
24. Lopez C., Comabella M., Al-zayat H., Tintore M., and Montalban X. Altered maturation of circulating dendritic cells in primary progressive MS patients. J. Neuroimmunol. 175 (2006) 183-191
25. Lucchinetti C., Bruck W., Parisi J., Scheithauer B., Rodriguez M., and Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann. Neurol. 47 (2000) 707-717
26. Martin R., Bielekova B., Hohlfeld R., and Utz U. Biomarkers in multiple sclerosis. Dis. Markers 22 (2006) 183-185
27. Martinez-Yelamos S., Martinez-Yelamos A., Martin Ozaeta G., Casado V., Carmona O., and Arbizu T. Regression to the mean in multiple sclerosis. Mult. Scler. 12 (2006) 826-829
28. McNeil B.J., and Hanley J.A. Statistical approaches to the analysis of receiver operating characteristic (ROC) curves. Med. Decis. Mak. 4 (1984) 137-150
29. Migita K., Miyashita T., Maeda Y., Kimura H., Nakamura M., Yatsuhashi H., et al. Reduced blood BDCA-2+ (lymphoid) and CD11c+ (myeloid) dendritic cells in systemic lupus erythematosus. Clin. Exp. Immunol. 142 (2005) 84-91
30. Navarro J., Aristimuno C., Sanchez-Ramon S., Vigil D., Martinez-Gines M.L., Fernandez-Cruz E., et al. Circulating dendritic cells subsets and regulatory T-cells at multiple sclerosis relapse: differential short-term changes on corticosteroids therapy. J. Neuroimmunol. (2006)
31. Ota M., Amakawa R., Uehira K., Ito T., Yagi Y., Oshiro A., et al. Involvement of dendritic cells in sarcoidosis. Thorax 59 (2004) 408-413
32. Ozaki Y., Amakawa R., Ito T., Iwai H., Tajima K., Uehira K., et al. Alteration of peripheral blood dendritic cells in patients with primary Sjogren's syndrome. Arthritis Rheum. 44 (2001) 419-431
33. Panitch H., Goodin D., Francis G., Chang P., Coyle P., O'Connor P., et al. Benefits of high-dose, high-frequency interferon beta-1a in relapsing-remitting multiple sclerosis are sustained to 16 months: final comparative results of the EVIDENCE trial. J. Neurol. Sci. 239 (2005) 67-74
34. Pashchenkov M.V., Pinegin B.V., Link K., and Boiko A.N. [Dendritic cells and their role in inflammation in the central nervous system]. Zh Nevrol Psikhiatr Im S S Korsakova (2003) 39-46
35. Pashenkov M., Huang Y.M., Kostulas V., Haglund M., Soderstrom M., and Link H. Two subsets of dendritic cells are present in human cerebrospinal fluid. Brain 124 (2001) 480-492
36. Pellegrini P., Totaro R., Contasta I., Berghella A.M., Russo T., Carolei A., et al. IFNbeta-1a treatment and reestablishment of Th1 regulation in MS patients: dose effects. Clin. Neuropharmacol. 27 (2004) 258-269
37. Poser C.M., Paty D.W., Scheinberg L., McDonald W.I., Davis F.A., Ebers G.C., et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann. Neurol. 13 (1983) 227-231
38. Resino S., Sanchez-Ramon S., Bellon J.M., Correa R., Abad M.L., and Munoz-Fernandez M.A. Immunological recovery after 3 years' antiretroviral therapy in HIV-1-infected children. Aids 16 (2002) 483-486
39. Rio J., Nos C., Tintore M., Tellez N., Galan I., Pelayo R., et al. Defining the response to interferon-beta in relapsing-remitting multiple sclerosis patients. Ann. Neurol. 59 (2006) 344-352
40. Roncarolo M.G., Levings M.K., and Traversari C. Differentiation of T regulatory cells by immature dendritic cells. J. Exp. Med. 193 (2001) F5-9
41. Sanchez-Ramón, S., Aristimuño, C., Navarro, J., Jiménez, B., Rodriguez-Mahou, M., Rodriguez-Saínz, C., et al. 2004. Mature Dendritic Cells Subsets are recruited in Cerebrospinal Fluid and may be locally priming T-cells and recruiting regulatory T-cells at First Clinical relapse of Multiple Sclerosis. Mult. Scler. Vol. 10, (Suppl 2), S171.
42. Sanchez-Ramon S., Navarro A.J., Aristimuno C., Rodriguez-Mahou M., Bellon J.M., Fernandez-Cruz E., et al. Pregnancy-induced expansion of regulatory T-lymphocytes may mediate protection to multiple sclerosis activity. Immunol. Lett. 96 (2005) 195-201
43. Serafini B., Rosicarelli B., Magliozzi R., Stigliano E., Capello E., Mancardi G.L., et al. Dendritic cells in multiple sclerosis lesions: maturation stage, myelin uptake, and interaction with proliferating T cells. J. Neuropathol. Exp. Neurol. 65 (2006) 124-141
44. Stasiolek M., Bayas A., Kruse N., Wieczarkowiecz A., Toyka K.V., Gold R., et al. Impaired maturation and altered regulatory function of plasmacytoid dendritic cells in multiple sclerosis. Brain 129 (2006) 1293-1305
45. Sturzebecher S., Wandinger K.P., Rosenwald A., Sathyamoorthy M., Tzou A., Mattar P., et al. Expression profiling identifies responder and non-responder phenotypes to interferon-beta in multiple sclerosis. Brain 126 (2003) 1419-1429
46. Tomassini V., Paolillo A., Russo P., Giugni E., Prosperini L., Gasperini C., et al. Predictors of long-term clinical response to interferon beta therapy in relapsing multiple sclerosis. J. Neurol. 253 (2006) 287-293
47. Uehira K., Amakawa R., Ito T., Tajima K., Naitoh S., Ozaki Y., et al. Dendritic cells are decreased in blood and accumulated in granuloma in tuberculosis. Clin. Immunol. 105 (2002) 296-303
48. Viglietta V., Baecher-Allan C., Weiner H.L., and Hafler D.A. Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J. Exp. Med. 199 (2004) 971-979